Mereo’s brittle bone drug likely to shrug off phase 2b fail, say analystsMereo’s drug candidate for brittle bone disease missed its primary endpoint in a recent phase 2b study, but Share XMereo’s brittle bone drug likely to shrug off phase 2b fail, say analystshttps://pharmaphorum.com/news/mereos-brittle-bone-drug-likely-to-shrug-off-phase-2b-fail-say-analysts/
UK biotech Mereo gears up for key brittle bone drug dataUK biotech Mereo BioPharma is hoping the coming months will transform its fortunes as it prepares for potentially Share XUK biotech Mereo gears up for key brittle bone drug datahttps://pharmaphorum.com/news/uk-biotech-mereo-gears-up-for-key-brittle-bone-drug-data/
